Immune-Onc Therapeutics
Total Awards:
1
Award Value:
$6,000,000
Institution type:
For profit
Short Name:
Immune-Onc Therapeutics
Awards to the Institution
| Program Type | Investigator | Grant Title | Award Value |
|---|---|---|---|
| Clinical Trial Stage Projects | Joseph Paul Woodard | Phase 1 Clinical Development of IO-202, A First-in-Class Antibody Targeting LILRB4, for the Treatment of AML with Monocytic Differentiation and CMML | $6,000,000 |
| Total: $6,000,000.00 |